Is IMVT or ZBIO more profitable?

Immunovant's return on equity of -69.59% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Zenas BioPharma N/A -122.45% -58.04%

Does the media refer more to IMVT or ZBIO?

In the previous week, Zenas BioPharma had 7 more articles in the media than Immunovant. MarketBeat recorded 12 mentions for Zenas BioPharma and 5 mentions for Immunovant. Zenas BioPharma's average media sentiment score of 0.40 beat Immunovant's score of -0.12 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 1 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ZBIO or RYTM?

In the previous week, Zenas BioPharma had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Zenas BioPharma and 4 mentions for Rhythm Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.40 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ZBIO or ALKS?

Alkermes has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zenas BioPharma $10M 184.46 -$377.74M -$8.99 N/A Alkermes $1.48B 4.75 $241.66M $0.38 109.87

Is ZBIO or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Zenas BioPharma's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -122.45% -58.04% Alkermes 3.96% 4.15% 2.19%

Does the media favor ZBIO or ALKS?

In the previous week, Zenas BioPharma had 8 more articles in the media than Alkermes. MarketBeat recorded 12 mentions for Zenas BioPharma and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.56 beat Zenas BioPharma's score of 0.40 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alkermes 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LGND or ZBIO?

In the previous week, Zenas BioPharma had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 12 mentions for Zenas BioPharma and 3 mentions for Ligand Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.40 beat Ligand Pharmaceuticals' score of 0.36 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 1 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zenas BioPharma (ZBIO) Competitors

$28.12 -0.19 (-0.65%)

As of 02:27 PM Eastern

Compare

ZBIO vs. IMVT, RYTM, ALKS, LGND, and CGON

Should you buy Zenas BioPharma stock or one of its competitors? Zenas BioPharma's main competitors and comparable companies include Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Zenas BioPharma has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Zenas BioPharma	$10M	184.46	-$377.74M	-$8.99	N/A

Immunovant's return on equity of -69.59% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Zenas BioPharma	N/A	-122.45%	-58.04%

In the previous week, Zenas BioPharma had 7 more articles in the media than Immunovant. MarketBeat recorded 12 mentions for Zenas BioPharma and 5 mentions for Immunovant. Zenas BioPharma's average media sentiment score of 0.40 beat Immunovant's score of -0.12 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market.

Immunovant currently has a consensus target price of $44.00, suggesting a potential upside of 30.87%. Zenas BioPharma has a consensus target price of $46.71, suggesting a potential upside of 65.07%. Given Zenas BioPharma's higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

47.1% of Immunovant shares are owned by institutional investors. 1.9% of Immunovant shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Zenas BioPharma beats Immunovant on 8 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to Rhythm Pharmaceuticals?

Zenas BioPharma (NASDAQ:ZBIO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Zenas BioPharma presently has a consensus price target of $46.71, indicating a potential upside of 65.07%. Rhythm Pharmaceuticals has a consensus price target of $140.67, indicating a potential upside of 51.53%. Given Zenas BioPharma's higher probable upside, equities research analysts plainly believe Zenas BioPharma is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Zenas BioPharma has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

In the previous week, Zenas BioPharma had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Zenas BioPharma and 4 mentions for Rhythm Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.40 beat Rhythm Pharmaceuticals' score of 0.26 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Zenas BioPharma's return on equity of -122.45% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Rhythm Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	184.46	-$377.74M	-$8.99	N/A
Rhythm Pharmaceuticals	$189.76M	33.52	-$196.54M	-$3.11	N/A

Summary

Zenas BioPharma and Rhythm Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to Alkermes?

Zenas BioPharma (NASDAQ:ZBIO) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, Zenas BioPharma had 8 more articles in the media than Alkermes. MarketBeat recorded 12 mentions for Zenas BioPharma and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.56 beat Zenas BioPharma's score of 0.40 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alkermes	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Alkermes shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zenas BioPharma presently has a consensus target price of $46.71, suggesting a potential upside of 65.07%. Alkermes has a consensus target price of $54.47, suggesting a potential upside of 30.47%. Given Zenas BioPharma's higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Zenas BioPharma has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Alkermes has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	184.46	-$377.74M	-$8.99	N/A
Alkermes	$1.48B	4.75	$241.66M	$0.38	109.87

Alkermes has a net margin of 3.96% compared to Zenas BioPharma's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Alkermes	3.96%	4.15%	2.19%

Summary

Alkermes beats Zenas BioPharma on 13 of the 17 factors compared between the two stocks.

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Zenas BioPharma's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Zenas BioPharma	N/A	-122.45%	-58.04%

Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	22.53	$124.45M	$9.35	32.40
Zenas BioPharma	$10M	184.46	-$377.74M	-$8.99	N/A

Ligand Pharmaceuticals has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ligand Pharmaceuticals currently has a consensus target price of $337.89, indicating a potential upside of 11.53%. Zenas BioPharma has a consensus target price of $46.71, indicating a potential upside of 65.07%. Given Zenas BioPharma's higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Zenas BioPharma had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 12 mentions for Zenas BioPharma and 3 mentions for Ligand Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.40 beat Ligand Pharmaceuticals' score of 0.36 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ligand Pharmaceuticals beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to CG Oncology?

Zenas BioPharma (NASDAQ:ZBIO) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

CG Oncology has lower revenue, but higher earnings than Zenas BioPharma. CG Oncology is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	184.46	-$377.74M	-$8.99	N/A
CG Oncology	$4.04M	1,478.36	-$160.99M	-$2.69	N/A

Zenas BioPharma has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Zenas BioPharma had 12 more articles in the media than CG Oncology. MarketBeat recorded 12 mentions for Zenas BioPharma and 0 mentions for CG Oncology. Zenas BioPharma's average media sentiment score of 0.40 beat CG Oncology's score of 0.00 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Zenas BioPharma	Neutral
CG Oncology	Neutral

Zenas BioPharma has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Zenas BioPharma currently has a consensus price target of $46.71, indicating a potential upside of 65.07%. CG Oncology has a consensus price target of $87.78, indicating a potential upside of 30.27%. Given Zenas BioPharma's higher possible upside, equities analysts clearly believe Zenas BioPharma is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

CG Oncology beats Zenas BioPharma on 9 of the 16 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.84B	$3.86B	$7.16B	$13.36B
Dividend Yield	N/A	3.65%	2.53%	17.32%
P/E Ratio	-3.14	13.05	274.85	26.18
Price / Sales	184.06	1,308.59	614.67	93.04
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	6.26	17.17	11.25	6.40
Net Income	-$377.74M	-$23.20M	$3.50B	$381.35M
7 Day Performance	2.50%	-2.52%	-1.57%	-0.45%
1 Month Performance	-14.11%	-10.24%	-5.91%	-4.34%
1 Year Performance	29.77%	19.44%	7.98%	1.90%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	2.4361 of 5 stars	$28.12 -0.7%	$46.71 +66.2%	+30.1%	$1.83B	$10M	N/A	167
IMVT Immunovant	1.9098 of 5 stars	$33.46 -0.1%	$44.00 +31.5%	+98.9%	$6.92B	N/A	N/A	315	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.693 of 5 stars	$95.71 -2.9%	$140.67 +47.0%	-6.3%	$6.75B	$239.92M	N/A	414
ALKS Alkermes	3.2731 of 5 stars	$40.80 +1.6%	$54.47 +33.5%	+34.4%	$6.74B	$1.48B	107.37	2,050
LGND Ligand Pharmaceuticals	3.3918 of 5 stars	$310.36 -1.2%	$337.89 +8.9%	+67.4%	$6.26B	$268.09M	33.19	47

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. IMVT, RYTM, ALKS, LGND, and CGON

How does Zenas BioPharma compare to Immunovant?

Summary

How does Zenas BioPharma compare to Rhythm Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Alkermes?

Summary

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Summary

How does Zenas BioPharma compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. IMVT, RYTM, ALKS, LGND, and CGON

How does Zenas BioPharma compare to Immunovant?

Which has preferable valuation and earnings, IMVT or ZBIO?

Is IMVT or ZBIO more profitable?

Does the media refer more to IMVT or ZBIO?

Which has more risk & volatility, IMVT or ZBIO?

Do analysts prefer IMVT or ZBIO?

Do institutionals & insiders hold more shares of IMVT or ZBIO?

Summary

How does Zenas BioPharma compare to Rhythm Pharmaceuticals?

Do analysts rate ZBIO or RYTM?

Which has more risk and volatility, ZBIO or RYTM?

Does the media prefer ZBIO or RYTM?

Is ZBIO or RYTM more profitable?

Which has preferable earnings and valuation, ZBIO or RYTM?

Summary

How does Zenas BioPharma compare to Alkermes?

Does the media favor ZBIO or ALKS?

Do insiders and institutionals have more ownership in ZBIO or ALKS?

Do analysts rate ZBIO or ALKS?

Which has more risk and volatility, ZBIO or ALKS?

Which has higher valuation and earnings, ZBIO or ALKS?

Is ZBIO or ALKS more profitable?

Summary

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Is LGND or ZBIO more profitable?

Which has better valuation & earnings, LGND or ZBIO?

Which has more risk and volatility, LGND or ZBIO?

Do insiders & institutionals believe in LGND or ZBIO?

Do analysts prefer LGND or ZBIO?

Does the media refer more to LGND or ZBIO?

Summary

How does Zenas BioPharma compare to CG Oncology?

Which has stronger valuation & earnings, ZBIO or CGON?

Which has more volatility and risk, ZBIO or CGON?

Do insiders and institutionals believe in ZBIO or CGON?

Does the media favor ZBIO or CGON?

Is ZBIO or CGON more profitable?

Do analysts prefer ZBIO or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools